×
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT

S.Korea says Samsung BioLogics violated accounting rule

Last Updated 12 July 2018, 08:09 IST

South Korea's top financial regulator said on Thursday that drug manufacturer Samsung BioLogics Co Ltd had violated accounting rules and it will report the case to prosecutors for potential investigation.

The decision came after a months-long review of BioLogics' bookkeeping when it switched in 2015 to valuing its stake in drugmaker Samsung Bioepis at fair market value instead of at book value.

The accounting switch helped BioLogics swing to a profit just ahead of its $2 billion IPO in 2016.

The company, which has denied any wrongdoing, was not immediately available for comments.

ADVERTISEMENT
(Published 12 July 2018, 08:03 IST)

Follow us on

ADVERTISEMENT
ADVERTISEMENT